Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-22
2006-08-22
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C514S231500, C548S527000, C549S058000, C544S146000
Reexamination Certificate
active
07094801
ABSTRACT:
The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formulaor its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
REFERENCES:
patent: 3862176 (1975-01-01), Fauran et al.
patent: 4085135 (1978-04-01), Kyogoku et al.
patent: 4522811 (1985-06-01), Epstein et al.
patent: 4698291 (1987-10-01), Koibuchi et al.
patent: 4855438 (1989-08-01), Kaulen et al.
patent: 4904697 (1990-02-01), Sunkara et al.
patent: 5068364 (1991-11-01), Takagaki et al.
patent: 5155250 (1992-10-01), Parker et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5380747 (1995-01-01), Medford et al.
patent: 5608095 (1997-03-01), Parker et al.
patent: 5631365 (1997-05-01), Rosenblum et al.
patent: 5744614 (1998-04-01), Merkle et al.
patent: 5750351 (1998-05-01), Medford et al.
patent: 5767115 (1998-06-01), Rosenblum et al.
patent: 5773209 (1998-06-01), Medford et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5783596 (1998-07-01), Medford et al.
patent: 5786355 (1998-07-01), Konno et al.
patent: 5792787 (1998-08-01), Medford et al.
patent: 5807884 (1998-09-01), Medford et al.
patent: 5808137 (1998-09-01), Bombardelli et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5821260 (1998-10-01), Medford et al.
patent: 5846959 (1998-12-01), Medford et al.
patent: 5877203 (1999-03-01), Medford et al.
patent: 5951841 (1999-09-01), Wehlage et al.
patent: 6046212 (2000-04-01), Zwaagstra et al.
patent: 6069148 (2000-05-01), Schmidt et al.
patent: 6140343 (2000-10-01), DeNinno et al.
patent: 6147089 (2000-11-01), DeNinno et al.
patent: 6147090 (2000-11-01), DeNinno et al.
patent: 6159988 (2000-12-01), Naik et al.
patent: 6162445 (2000-12-01), Bernardon
patent: 6197786 (2001-03-01), DeNinno et al.
patent: 6310075 (2001-10-01), DeNinno et al.
patent: 6313142 (2001-11-01), Damon et al.
patent: 6423740 (2002-07-01), Bombardelli et al.
patent: 6462075 (2002-10-01), Bowen et al.
patent: 6608101 (2003-08-01), Ni et al.
patent: 6677350 (2004-01-01), Lin
patent: 2003/0232877 (2003-12-01), Sikorski et al.
patent: 2003/0236298 (2003-12-01), Meng et al.
patent: 2004/0048858 (2004-03-01), Sikorski et al.
patent: 307762 (1989-03-01), None
patent: 0 271 307 (1992-01-01), None
patent: 0 476 658 (1992-03-01), None
patent: 2175634 (1973-10-01), None
patent: 1408754 (1975-10-01), None
patent: 63010720 (1986-07-01), None
patent: 04217621 (1990-10-01), None
patent: 06092950 (1992-09-01), None
patent: 06116206 (1992-10-01), None
patent: 07330814 (1994-06-01), None
patent: WO 95/15760 (1995-06-01), None
patent: WO 96/08484 (1996-03-01), None
patent: WO 96/20936 (1996-07-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/33882 (1997-09-01), None
patent: WO 98/04528 (1998-02-01), None
patent: WO 98/23581 (1998-06-01), None
patent: WO 98/23581 (1998-06-01), None
patent: WO 98/35937 (1998-08-01), None
patent: WO 98/40375 (1998-09-01), None
patent: WO 98/51289 (1998-11-01), None
patent: WO 98/51662 (1998-11-01), None
patent: WO 99/00114 (1999-01-01), None
patent: WO 99/00114 (1999-01-01), None
patent: WO 99/14174 (1999-03-01), None
patent: WO 99/14215 (1999-03-01), None
patent: WO 99/15504 (1999-04-01), None
patent: WO 00/18721 (2000-06-01), None
patent: WO 00/18723 (2000-06-01), None
patent: WO 00/18724 (2000-06-01), None
patent: WO 00/38725 (2000-07-01), None
patent: WO 00/47554 (2000-08-01), None
patent: WO 00/17166 (2003-03-01), None
patent: WO 04/056727 (2004-07-01), None
Liu et al., Antimalarial Alkoxylated and Hydroxylated Chalones: Structure-Activity Relationship Analysis,J. Med. Chem. 2001, 44, 4443-4452.
Herencia et al, Novel Anti-inflammatory Chalcone Derivatives Inhibit the Induction of Nitric Oxide Synthase and Cyclooxygenase-2 in Mouse Peritoneal Macrophages,FEBS Letters, 1999, 453, 129-134.
Herencia, et al., in Synthesis and Anti-inflammatory Activity of Chalcone Derivatives,Bioorganic&Medicinal Chemistry Letters 8(1998) 1169-1174.
Hsieh et al., Synthesis and Anti-inflammatory Effect of Chalcones and Related Compounds,Pharmaceutical Research, 1998, vol. 15, No. 1, 39-46.
Hsieh, et al., Synthesis and Anti-inflammatory Effect of Chalcones,J. Pharm. Pharmacol. 2000, 52; 163-171..
Jones R. and N. Bischofberger,Antiviral Research, 27 (1995) 1-17.
Yang, Y., et al.,Heterocycles, 1992, 34(6), 1169-1175.
Zwaagstra, et al., Synthesis and Structure-Activity Relationships of Carboxylated Chalcones: A Novel Series of CysLT1(LT4) Receptor Antagonists; J. Med. Chem., 1997, 40, 1075-1089.
Abraham, W., et al., “Blockade of Late-phase Airway Reponses and Airway Hyperresponsiveness in Allergic Sheep with a Small-molecule Peptide Inhibitor of VLA-4,”Am. J. Respir. Crit. Care Med., 156:696-703 (1997),.
Albertini, J.P., et al., “Increase in Serum Levels of Adhesion Glycoprpteins in NIDDM Effect of Intensive Insulin Treatment,”Diabetologia, 39:A240 (1996).
Bakhite, E. A., et al., “Synthesis and application of some new oxazole derivatives as antimicrobial agents,”J. Chem. Tech. Biotech., 55:157-161 (1992).
Baraczka, K., et al., “A Study Of Increased Levels Of Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) In The Cerebrospinal Fluid of Patients With Multiple Sclerosis And systemic Lupus Erythematosus,”Acta. Neurol. Scand., 99:95-99 (1999).
Belmont, H.M., et. al., “Up-Regulation of Endothelial Cell Adhesion Molecules Characterizes Disease Activity in Systemic Lupus Erythematosus,”Arthritis&Rheumatism, 37(3):376-383 (1994).
Boratynska, M., et al., :Soluble cell adhesion molecules in chronic renal graft rejection,Pol. Arch. Med. Wewn, 100:410-418 (1998).
Bousquet, J., et. al., “Eosinophilic Inflammation in Asthma”N. Engl. J. Med., 323(15):1033-1039 (1990).
Braunstahl,G.J., et. al., “Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways,”J. Allergy Clin. Immunol., 107:469-476 (2001).
Calliste, C.-A., et al., “Chalcones: Structural Requirements for Antioxidant, Estrogenic and Antiproliferative Activities,”Anticancer Research, 21:3949-3956 (2001).
Cheng, Z.-J., et al., “Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipoplysaccharide-activated macrophages,”Biochemical Pharmacology, 61:939-946 (2001).
Corey, E.J., et al., “A synthetic method for formyl-ethynyl conversion (RCHO→RC═CH or RC═CR1),”Tetrahedron Letters, 1972(36):3769-3772 (1972).
Cosimi, A.B., et al., “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts,”J. Immunol., 144(12):4604-4612 (1990).
Dimmock, J.R., et al., “Cytotoxic Activities of Mannich Bases of Chalcones and Related Compounds,”J. Med. Chem., 41(7):1014-1026 (1998).
Dimmock, J.R., et al., “Bioactivities of chalcones,”Current Medicinal Chemistry, 6(12):1125-1149 (1999).
Dinkova-Kostova, A.T., et al., “Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups,”Proc. Natl. Acad. Sci. U.S.A., 98(6):3404-3409 (Mar. 13, 2001).
Elovaara, I., et al., “Adhesion Molecules in Multiple Sclerosis,”Arch. Neurol., 57:546-551 (2000).
Endo, A., “The discovery and development of HMG-CoA reductase inhibitors,”J. Lipid Res., 33:1569-1582 (1992).
Enghofer, M., et al., “Vascular Cell Adhesion Molecule 1 Mediates Islet Lymphocyte Adhession in Diabetic Insulitis in Mice,”Diabetologia, 39:A97 (1996).
Frigerio, S.,et al., “Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients,”Neuroimmunol., 87:88-93 (1998).
Furuzawa-Carballeda, J., et al., “Interleukin-8, interleukin-10, intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Expression Levels are Higher in Synovial Tissue for Patients with Rheumatoid Arthritis than in Ost
Meng Charles Q.
Ni Liming
Sikorski James A.
Weingarten M. David
Worsencroft Kimberly J.
Atherogenics, Inc.
King&Spalding, LLP
Knowles, Esq. Sherry M.
Lambkin Deborah C.
LandOfFree
Chalcone derivatives and their use to treat diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chalcone derivatives and their use to treat diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chalcone derivatives and their use to treat diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3699984